Serum Concentrations of Pentraxin3 in Patients With Acute Coronary Syndrome: A Case-Control Study

Document Type : Original Article


Research Centre for Non-Communicable Diseases, Medical School. Jahrom University of Medical Sciences, Jahrom, IR Iran.


Background: Cardiovascular diseases are the first and the most common cause of death in Iran. Pentraxin3 (PTX3) is an inflammatory marker that increases in patients with acute myocardial infarction. This study aimed to compare the PTX3 level among patients with acute coronary syndrome (ACS).
Methods: The present study enrolled 130 patients with ACS and 82 subjects as the control group. Within 12 hours of the onset of chest pain, 5 mL of blood was obtained from the antecubital vein. Then, serum was separated by centrifugation and stored at –70 °C until the measurement of PTX3. The level of PTX3 was measured using an enzyme-linked immunosorbent assay kit. Data were recorded and analyzed by SPSS version 16.0. A P-value of less than 0.05 was considered statistically significant.
Results: The distribution of age, sex, diabetes mellitus, hypertension, and hyperlipidemia was similar in both the ACS and control groups, but it was not similar for smoking. Serum PTX3 was significantly higher in the ACS group. The serum PTX3 level was higher in the subgroup with ST-segment elevation myocardial infarction than in the subgroups with unstable angina pectoris, stable angina pectoris, and noncardiac diseases. Additionally, patients with unstable angina pectoris had higher PTX3 than those with stable angina pectoris and noncardiac diseases.
Conclusions: Our results suggest that PTX3 may be released by systemic inflammation at the very onset of acute myocardial infarction. (Iranian Heart Journal 2021; 22(3): 64-73)


  1. Dahlof B. Cardiovascular disease risk factors: epidemiology and risk assessment. The American Journal of Cardiology. 2010;105:3A-9A.
  2. Ahmadi A, Soori H, Mobasheri M, Etemad K, Khaledifar A. Haert failure, the outcomes, predictive and related factors in Iran. J Mazandaran Univ Med Sci. 2014;24:180-8.
  3. Lusis AJ. Atherosclerosis. Nature. 2000;407:233-41.
  4. Libby P, Pidker PM, Hansson GK. Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol. 2009;54:2129-38.
  5. Hodžić E, Hasković E, Duraković M, Fočak M. Troponin and C-reactive protein in risk stratification after myocardial infarction. Acta facultatis medicae Naissensis. 2017;34(3):213-20.
  6. Jahromi AS, Shojaie M, Madani A. Cardiotrophin-1 in patients with acute myocardial infarction. American Journal of Applied Sciences. 2010;7(9):1190-4.7.
  7. Koo BK, Choi DH, Ryu SK, Role of inflammation on coronary artery disease in Koreans. Korean Circ J. 2002;32:988-95.
  8. Liuzzo G, Biasucci LM, Gallimore JR, Grillo RL, Rebuzzi AG, Pepys MB, et al. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med. 1994;331:417-24.
  9. Shojaei M, Erfanian S, Taghipour N, Jahromia AS, Khoshfetrat M, Madani A, et al. Serum levels of β2-Microglobulin and high sensitive C-reactive protein in ST-elevated and non. ST-elevated myocardial infarction. Pakistan Journal of Medical and Health Sciences. 2018;12:880-3.
  10. CieSlik P, Hrycek A. Long pentraxin 3 (PTX3) in the light of its structure, mechanism of action and clinical implications. Autoimmunity. 2012;45(2):119-28.
  11. Maseri A, Fuster V. Is there a vulnerable plaque? Circulation. 2003;107(16):2068-71.
  12. Garlanda C, Bottazzi B, Bastone A, Mantovani A. Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility. Annu Rev Immunol. 2005;23:337-66.
  13. Mantovani A, Garlanda C, Bottazzi B. Pentraxin 3, a non-redundant soluble pattern recognition receptor involved in innate immunity. Vaccine. 2003;21(suppl 2):S43-S7.
  14. Napoleone E, Di Santo A, Bastone A, Peri G, Mantovani A, de Gaetano G, et al. Long Pentraxin PTX3 Upregulates Tissue Factor Expression in Human Endothelial Cells. A Novel Link Between Vascular Inflammation and Clotting Activation. 2002;22(5):782-7.
  15. Mantovani A, Garlanda C, Bottazzi B, Peri G, Doni A, Martinez de la Torre Y, et al. The long pentraxin PTX3 in vascular pathology. Vascul Pharmacol. 2006;45:326-30.
  16. Norata GD, Garlanda C, Catapano AL. The long pentraxin PTX3: a modulator of the immunoinflammatory response in atherosclerosis and cardiovascular diseases. Trends in Cardiovascular Medicine. 2010;20:35-40.
  17. Kume N, Mitsuoka H, Hayashida K, Tanaka M. Pentraxin 3 as a biomarker for acute coronary syndrome: Comparison with biomarkers for cardiac damage. Journal of Cardiology. 2011;58(1):38-45.
  18. Matsuura Y, Hatakeyama K, Imamura T, Tsuruda T, Shibata Y, Kodama T, et al. Different distribution of pentraxin 3 and C-reactive protein in coronary atherosclerotic plaques. Journal of Atherosclerotic and Thrombosis. 2012;19(9):837-45.
  19. Matsui S, Ishii J, Kitagawa F, Kuno A, Hattori K, Ishikawa M, et al. Pentraxin 3 in unstable angina and non-ST-segment elevation myocardial infarction. Atherosclerosis. 2010;210(1):220-5.
  20. Inoue K, Sugiyama A, Reid PC, Ito Y, Miyauchi K, Mukai S, et al. Establishment of a high sensitivity plasma assay for human pentraxin3 as a marker for unstable angina pectoris. Arterioscler Thromb Vasc Biol. 2007;27:161-7.
  21. Peri G, Introna M, Corradi D, Iacuitti G, Signorini S, Avanzini F, et al. PTX3, A Prototypical Long Pentraxin, Is an Early Indicator of Acute Myocardial Infarction in Humans. Circulation. 2000;102:636-41.
  22. Barbati E, Specchia C, Villella M, Rossi ML, Barlera S, Bottazzi B, et al. Influence of Pentraxin 3 (PTX3) Genetic Variants on Myocardial Infarction Risk and PTX3 Plasma Levels. PLoS ONE. 2012;7(12):e53030.
  23. Salio M, Chimenti S, De-Angelis N, Molla F, Maina V, Nebuloni M, et al. Cardioprotective Function of the Long Pentraxin PTX3 in Acute Myocardial Infarction. Circulation. 2008;117(8):1055-64.
  24. Ustundag M, Orak M, Guloglu C, Sayhan MB, Alyan O, Kale E. Comparative diagnostic accuracy of serum levels of neutrophil activating peptide-2 and pentraxin-3 versus troponin-I in acute coronary syndrome. Anadolu Kardiyol Derg. 2011;11:588-94.
  25. Jenny NS, Arnold AM, Kuller LH, Tracy RP, Psaty BM. Associations of pentraxin 3 with cardiovascular disease and all-cause death: the Cardiovascular Health Study. Arterioscler Thromb Vasc Biol. 2009;29:594–9.
  26. Inoue K, Kodama T, Daida H. Pentraxin 3: A Novel Biomarker for Inflammatory Cardiovascular Disease. International Journal of Vascular Medicine. 2012;2012:e657025.
  27. Shojaei M, Rahmanian K, Moayedy-Rad M. Association of Rose angina with cardiovascular risk factors among men and women: a population-based study. Jentashapir J Health Res. 2014;5(1):477-82.
  28. Shojaei M, Sotoodeh-Jahromi A, Rahmanian K, Madani A. Gender Differences in the Prevalence of Cardiovascular Risk Factors in an Iranian Urban Population. OnLine Journal of Biological Sciences. 2015;15(3):178-84.
  29. Rahmanian K, Shojaie M. The prevalence of pre-hypertension and its association to established cardiovascular risk factors in south of Iran. BMC Research Notes. 2012;5:386.
  30. Yamashina A, Tomiyama H, Arai T, Hirose K, Koji Y, Hirayama Y, et al. Brachial-ankle pulse wave velocity as a marker of atherosclerotic vascular damage and cardiovascular risk. Hypertens Res. 2003;26:615– 22.
  31. Barazzoni R, Aleksova A, Carriere C, Cattin MR, Zanetti M, Vinci P, et al. Obesity and high waist circumference are associated with low circulating pentraxin-3 in acute coronary syndrome. Cardiovascular Diabetology. 2013;12:167.
  32. Guo T, Huang L, Liu C, Shan S, Li Q, Ke L, et al. The clinical value of inflammatory biomarkers in coronary artery disease: PTX3 as a new inflammatory marker. Exp Gerontol. 2017;97:64-7.
  33. Wu L-P, Song X-F, Zhang S-Q, Tang J-F, Yang P-L. The Relationship of Pentraxin-3 with Acute Coronary Syndrome and Coronary Artery Lesion. Chinese Journal of Arteriosclerosis. 2007;12:016.
  34. Özer MR, Ergin M, Kılınç İ, Dündar ZD, Özer N, Önal MA, et al. Diagnostic and Prognostic Significance of Neutrophil Gelatinase-Associated Lipocalin and Pentraxin-3 in Acute Coronary Syndrome. Eurasian J Emerg Med. 2017;16: 12-8.
  35. El-Melegy EK, E.A B, El-Kersh AM, EL-Shafey WH, Fareed WA. Pentraxin 3 genotyping in relation to serum levels of pentraxin 3 in patients with acute ST-segment elevation myocardial infarction. Clin Trials Regul Sci Cardiol. 2016;13:6-13.
  36. Yamasaki T, Koizumi T, Tamaki T, Sakamoto A, Kikutani T, Sano K, et al. Differing Behavior of Plasma Pentraxin3 and High-Sensitive CRP at the Very Onset of Myocardial Infarction with ST-segment Elevation. Angiol. 2013;1:108.
  37. Saygı S, Kırılmaz B, Tengiz İ, Türk UO, Yıldız H, Tüzün N, et al. Long pentraxin-3 measured at late phase associated with GRACE risk scores in patients with non-ST elevation acute coronary syndrome and coronary stenting. Arch Turk Soc Cardiol. 2012;40(3):205-12.
  38. Eggers KM, Armstrong PW, Califf RM, Johnston N, Simoons ML, Venge P, et al. Clinical and prognostic implications of circulating pentraxin 3 levels in non ST-elevation acute coronary syndrome. Clin Biochem. 2013;46(16-17):1655-9.
  39. Soeki T, Niki T, Kusunose K, Bando S, Hirata Y, Tomita N, et al. Elevated concentrations of pentraxin 3 are associated with coronary plaque vulnerability. Journal of Cardiology. 2011;58(2):151-7.
  40. Karakas MF, Buyukkaya E, Kurt M, Motor S, Akcay AB, Buyukkaya Ş, et al. Serum Pentraxin 3 Levels Are Associated With the Complexity and Severity of Coronary Artery Disease in Patients With Stable Angina Pectoris. Journal of Investigative Medicine. 2013;61(2):278–85.
  41. Rolph MS, Zimmer S, Bottazzi B, Garlanda C, Mantovani A, Hansson GK. Production of the long pentraxin PTX3 in advanced atherosclerotic plaques. Arterioscler Thromb Vasc Biol. 2002;22(5):e10-e4.
  42. Norata GD, Marchesi P, Venu VKP, Pasqualini F, Anselmo A, Moalli F, et al. Deficiency of the long pentraxin PTX3 promotes vascular inflammation and atherosclerosis. Circulation. 2009;120(8):699-708.
  43. Kotooka N, Inoue T, Fujimatsu D, Morooka T, Hashimoto S, Hikichi Y, et al. Pentraxin3 is a novel marker for stent-induced inflammation and neointimal thickening. Atherosclerosis. 2008;197(1):368-74.
  44. Latini R, Maggioni AP, Peri G, Gonzini L, Lucci D, Mocarelli L, et al. Prognostic significance of the long pentraxin PTX3 in acute myocardial infarction. Circulation. 2004;110:2349-54.
  45. Shim B-J, Jeon H-K, Lee S-J, Kim S-S, Park M-Y, Lee D-H, et al. The Relationship Between Serum Pentraxin 3 and Central Obesity in ST-Segment Elevation Myocardial Infarction Patients. Korean Circ J. 2010;40:308-13.
  46. Suzuki S, Takeishi Y, Niizeki T, Koyama Y, Kitahara T, Pentraxin 3, a new marker for vascular inflammation, predicts adverse clinical outcomes in patients with heart failure. Am Heart J. 2008;155:75–81.
  47. Haybar H, Davoodi M, Shahlaee A, Eslami.Shahr.Babaki A, Fazelinezhad Z, Azarian M, et al. The implication of calcium score and pentraxin-3 in non-invasive identification of significant coronary artery stenosis in chronic stable angina pectoris. World Journal of Cardiovascular Diseases. 2013;3:433-41.